Mahamaya Lifesciences Ltd (544611)

Mahamaya Lifesciences announced that its shareholders approved significant leadership changes at the meeting held on September 29, 2026. Founder Mr. Krishnamurthy Ganesan has been re-designated from Managing Director to Chairman effective November 01, 2026. Concurrently, Executive Director Mr. Prashant Krishnamurthy has been elevated to Managing Director effective November 01, 2026, marking a planned generational succession. Additionally, the company regularized Dr. Bhagirath Choudhary as Independent Director for a 3-year term from August 25, 2026, and re-appointed two Independent Directors for second 3-year terms starting December 11, 2026.

• Prashant Krishnamurthy elevated to Managing Director effective November 01, 2026
• Founder Krishnamurthy Ganesan transitioned from MD to Chairman effective November 01, 2026
• Dr. Bhagirath Choudhary appointed Independent Director for a 3-year term starting August 25, 2026
• Dr. Gopal Krishna Raju and Dr. Charudatta Digambar Mayee re-appointed as Independent Directors for 3-year terms effective December 11, 2026

Mahamaya Lifesciences announced a planned leadership succession approved at its Board meeting on August 25, 2026. Prashant Krishnamurthy will step down as CFO on October 31, 2026, and take over as Managing Director effective November 01, 2026, while current MD Krishnamurthy Ganesan transitions to Executive Chairman. Amarendra Mohapatra has been elevated to the position of Chief Financial Officer effective November 01, 2026. Additionally, the Board appointed Bhagirath Choudhary as Additional Independent Director for a 3-year term and scheduled the 24th AGM for September 29, 2026.

• Prashant Krishnamurthy re-designated from Executive Director & CFO to Managing Director effective November 01, 2026
• Current MD Krishnamurthy Ganesan transitions to Chairman and Executive Non-Independent Director from November 01, 2026
• Amarendra Mohapatra appointed as Chief Financial Officer and KMP effective November 01, 2026
• Bhagirath Choudhary appointed as Additional Independent Director for a 3-year term effective August 25, 2026
• 24th Annual General Meeting (AGM) scheduled for September 29, 2026

Mahamaya Lifesciences Limited has announced a leadership transition approved by its Board on August 25, 2026. Mr. Prashant Krishnamurthy will step down as CFO on October 31, 2026, and assume the role of Managing Director effective November 01, 2026, while current MD Mr. Krishnamurthy Ganesan transitions to Chairman and Executive Director. Mr. Amarendra Mohapatra has been elevated to Chief Financial Officer effective November 01, 2026, and Mr. Kush Mishra was appointed Company Secretary effective August 25, 2026.

• Prashant Krishnamurthy re-designated as Managing Director effective November 01, 2026
• Krishnamurthy Ganesan transitions from MD to Chairman and Executive Director effective November 01, 2026
• Amarendra Mohapatra appointed as Chief Financial Officer (CFO) effective November 01, 2026
• 24th AGM scheduled for September 29, 2026 to approve director appointments and remuneration revisions

Mahamaya Lifesciences announced a major executive leadership restructuring following its board meeting on August 25, 2026. Managing Director Krishnamurthy Ganesan will step down to become Chairman and Executive Non-Independent Director effective November 1, 2026. Prashant Krishnamurthy will transition from CFO/Executive Director to Managing Director, while Amarendra Mohapatra takes over as the new Chief Financial Officer. Additionally, Kush Mishra has been appointed as Company Secretary and Compliance Officer effective August 25, 2026, and the 24th AGM is scheduled for September 29, 2026.

• Prashant Krishnamurthy re-designated as Managing Director and steps down as CFO effective November 01, 2026
• Amarendra Mohapatra elevated to Chief Financial Officer (CFO) effective November 01, 2026
• Krishnamurthy Ganesan transitions from MD to Chairman & Executive Director effective November 01, 2026
• Kush Mishra appointed as Company Secretary and Compliance Officer effective August 25, 2026
• 24th Annual General Meeting (AGM) scheduled for September 29, 2026

Mahamaya Lifesciences has released its investor presentation ahead of a scheduled investor meet on August 07, 2026. The company reported a revenue of ₹329.0 cr in FY26, representing a 24.6% growth over FY25's ₹264.0 cr. Operating margins improved slightly to 10.0% in FY26 from 9.0% in the previous year. The company maintains a healthy ROCE of 20.0% with a debt-to-equity ratio of 0.75.

• Investor Meet scheduled for August 07, 2026, at 04:00 pm IST.
• FY26 annual revenue reached ₹329.0 cr, up from ₹264.0 cr in FY25.
• Operating Profit Margin (OPM) improved to 10.0% in FY26 from 9.0% in FY25.
• Net profit for FY26 stood at ₹17.0 cr compared to ₹13.0 cr in FY25.
• Company maintains a debt of ₹91 cr against a net worth of ₹122 cr (D/E 0.75).

Mahamaya Lifesciences has scheduled a virtual group meeting with investors and analysts for August 07, 2026, at 04:00 PM IST. The meeting will focus on publicly available information, following a fiscal year (FY26) where the company reported revenue of ₹329.0 cr and a net profit of ₹17.0 cr. This is a routine engagement aimed at transparency with the investment community. Management has clarified that no unpublished price-sensitive information (UPSI) will be shared during the session.

• Virtual group meeting scheduled for August 07, 2026, at 04:00 PM IST
• Company reported FY26 revenue of ₹329.0 cr, a 24.6% increase over FY25
• Net profit for FY26 reached ₹17.0 cr compared to ₹13.0 cr in the previous year
• Intimation filed under Regulation 30 and 46(2) of SEBI LODR Regulations

Ms. Shilpi Bhardwaj has resigned from her position as Company Secretary, Compliance Officer, and Key Managerial Personnel (KMP) of Mahamaya Lifesciences Ltd. The resignation was tendered on June 10, 2026, and she was relieved from her duties at the close of business hours on July 30, 2026. The company cited her pursuit of alternate career opportunities as the reason for departure. This is a routine administrative change for the company, which reported a revenue of ₹329.0 Cr in FY26.

• Resignation effective from the close of business hours on July 30, 2026
• The resignation letter was originally submitted on June 10, 2026
• The outgoing official held three concurrent roles: Company Secretary, Compliance Officer, and KMP
• Company reported FY26 revenue of ₹329.0 Cr and net profit of ₹17.0 Cr

Mahamaya Lifesciences has informed the exchange that it is exempt from submitting the quarterly Corporate Governance Report for the period ended June 30, 2026. This exemption is granted under Regulation 15(2)(b) of SEBI (LODR) Regulations, 2015, because the company's shares are listed on the BSE SME platform. A certificate from HPN & Associates, Company Secretaries, confirms this non-applicability. This is a standard procedural filing for SME-listed entities and does not reflect any change in business operations.

• Exemption claimed under Regulation 15(2)(b) of SEBI (LODR) Regulations, 2015
• Applicable for the quarter ended 30 June 2026
• Company is listed on the SME Platform of BSE Limited
• Certificate of non-applicability issued by HPN & Associates on 10 July 2026